SCHEMBL20187959

SCHEMBL20187959

CCOC(=O)c1ccc(OC)c(-n2c(N)nnc2-c2cccs2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 6/20 0.65
MAPT P10636 5/20 0.49
HPGD P15428 4/20 0.49
TSHR P16473 2/20 0.49
HSD17B10 Q99714 5/20 0.46
ALDH1A1 P00352 4/20 0.46
ALOX15 P16050 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
KDM4E B2RXH2 3/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.44
GLA P06280 1/20 0.42
GAA P10253 2/20 0.42
TNFRSF1A P19438 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20187769 0.79 APLNR (1.00) APLNRHPGDTSHRHSD17B10ALDH1A1
SCHEMBL20190468 0.77 APLNR (1.00) APLNRHPGDTSHRHSD17B10ALDH1A1
SCHEMBL17298109 0.77 APLNR (0.74) APLNRMAPTHPGDTSHRHSD17B10
SCHEMBL20207578 0.77 APLNR (0.75) APLNRTSHR
SCHEMBL20189127 0.76 APLNR (1.00) APLNR
Hydrochloric Acid SCHEMBL19095396 0.76 APLNR (0.73) APLNRMAPTHPGDTSHRHSD17B10
Hydrochloric Acid SCHEMBL31608490 0.76 APLNR (0.73) APLNRMAPTHPGDTSHRHSD17B10
SCHEMBL20189712 0.75 APLNR (1.00) APLNRTSHRHSD17B10MAPK1
SCHEMBL20189941 0.71 APLNR (1.00) APLNRHPGDTSHRHSD17B10ALDH1A1
SCHEMBL30506315 0.69 HSD17B2 (0.76) MAPTTSHRALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS Amgen Inc. (US) 2019-09-25 EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R APLNR 13/4885MAPT 4115/4885HPGD 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.